- Novo Nordisk to acquire all outstanding shares of Emisphere for $1.35B and also acquires royalty stream obligations to the firm’s biggest shareholder (MHR) for $450M, making a total deal value as $1.8B
- Novo Nordisk eliminates its future royalty obligations to Emisphere and MHR & obtains full access to the Eligen SNAC technology platform, thus enabling Novo Nordisk to expand its portfolio of oral biologics across therapy areas
- The acquisition will provide Novo Nordisk full rights of the Eligen’s SNAC technology, which has been used under a 2007 license agreement to develop the first oral biologic, Rybelsus for T2D
Click here to read full press release/ article | Ref: Novo Nordisk | Image: SRX
The post Novo Nordisk to Acquire Emisphere Technologies for .8B first appeared on PharmaShots.